JP6872550B2 - 架橋されたピペリジン誘導体 - Google Patents

架橋されたピペリジン誘導体 Download PDF

Info

Publication number
JP6872550B2
JP6872550B2 JP2018529006A JP2018529006A JP6872550B2 JP 6872550 B2 JP6872550 B2 JP 6872550B2 JP 2018529006 A JP2018529006 A JP 2018529006A JP 2018529006 A JP2018529006 A JP 2018529006A JP 6872550 B2 JP6872550 B2 JP 6872550B2
Authority
JP
Japan
Prior art keywords
azabicyclo
octane
triazolo
amine
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018529006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536671A5 (enExample
JP2018536671A (ja
Inventor
バルテルス，ビョルン
バウマン，カールハインツ
ガレイ，グイド
ヤーシュケ，ゲオルク
ヤーコップ−ルートネ，ローラント
リンベルク，アンニャ
ナイトハルト，ヴェルナー
ラトニ，アサヌ
ロドリゲス−サルミエント，ロサ・マリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2018536671A publication Critical patent/JP2018536671A/ja
Publication of JP2018536671A5 publication Critical patent/JP2018536671A5/ja
Application granted granted Critical
Publication of JP6872550B2 publication Critical patent/JP6872550B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018529006A 2015-12-10 2016-12-06 架橋されたピペリジン誘導体 Active JP6872550B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15199260 2015-12-10
EP15199260.9 2015-12-10
PCT/EP2016/079816 WO2017097728A1 (en) 2015-12-10 2016-12-06 Bridged piperidine derivatives

Publications (3)

Publication Number Publication Date
JP2018536671A JP2018536671A (ja) 2018-12-13
JP2018536671A5 JP2018536671A5 (enExample) 2019-12-12
JP6872550B2 true JP6872550B2 (ja) 2021-05-19

Family

ID=54848457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018529006A Active JP6872550B2 (ja) 2015-12-10 2016-12-06 架橋されたピペリジン誘導体

Country Status (7)

Country Link
US (2) US10562903B2 (enExample)
EP (1) EP3386978B1 (enExample)
JP (1) JP6872550B2 (enExample)
CN (1) CN108137579B (enExample)
AR (1) AR107010A1 (enExample)
TW (1) TWI629278B (enExample)
WO (1) WO2017097728A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100506T1 (it) 2015-10-02 2021-11-12 Hoffmann La Roche Anticorpi bispecifici specifici per pd1 e tim3
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
EP3475279B1 (en) * 2016-06-27 2021-07-14 F. Hoffmann-La Roche AG Triazolopyridines as gamma-secretase modulators
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3535266B1 (en) * 2016-11-01 2021-12-29 F. Hoffmann-La Roche AG Bicyclic heteroaryl derivatives
KR20190121816A (ko) 2017-04-03 2019-10-28 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
PL3606955T3 (pl) 2017-04-05 2025-02-24 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
WO2020048904A1 (en) 2018-09-03 2020-03-12 F. Hoffmann-La Roche Ag Bicyclic heteroaryl derivatives
SI3894411T1 (sl) * 2018-12-13 2024-10-30 F. Hoffmann - La Roche Ag Derivati 7-fenoksi-N-(3-azabiciklo(3.2.1)oktan-8-il)-6,7-dihidro-5H- pirolo(1,2-b)(1,2,4)triazol-2-amina in sorodne spojine kot modulatorji gama-sekretaze za zdravljenje Alzheimerjeve bolezni
JP2022515610A (ja) 2018-12-27 2022-02-21 エフ．ホフマン－ラ ロシュ アーゲー ｅｘｏ－ｔｅｒｔ－ブチルＮ－（３－アザビシクロ［３．２．１］オクタン－８－イル）カルバミン酸塩の調製のためのプロセス
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
WO2022238816A1 (en) * 2021-05-14 2022-11-17 Bm Pharma Consulting Pty. Ltd Bicyclic heterocyclic compounds for prophylaxis and treatment of viral infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
KR20060127909A (ko) 2003-12-24 2006-12-13 비오타 사이언티픽 매니지먼트 피티와이 엘티디 호흡기 다핵체 바이러스 감염 치료용 다환 물질
BRPI0616667B1 (pt) * 2005-10-06 2017-07-18 Nippon Soda Co. , Ltd. Compounds of cyclical amine or salts thereof or non-oxides thereof, and agents for control of fever
FR2914188B1 (fr) 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
JP2011529722A (ja) 2008-08-14 2011-12-15 カーディアック ペースメイカーズ， インコーポレイテッド 音響通信リンクの性能評価および適合
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
ES2733644T3 (es) 2012-01-26 2019-12-02 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
WO2014012050A2 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
WO2014184163A1 (en) 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
RU2673542C2 (ru) 2013-06-25 2018-11-28 Ф. Хоффманн-Ля Рош Аг Соединения для лечения спинальной мышечной атрофии
AR099134A1 (es) 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
DK3143025T3 (da) 2014-05-15 2019-12-09 Hoffmann La Roche Forbindelser til behandling af spinal muskelatrofi
JP6659841B2 (ja) 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物

Also Published As

Publication number Publication date
US10562903B2 (en) 2020-02-18
EP3386978A1 (en) 2018-10-17
CN108137579A (zh) 2018-06-08
EP3386978B1 (en) 2021-01-27
TW201725209A (zh) 2017-07-16
JP2018536671A (ja) 2018-12-13
US20190010156A1 (en) 2019-01-10
WO2017097728A1 (en) 2017-06-15
AR107010A1 (es) 2018-03-14
US20200291034A1 (en) 2020-09-17
CN108137579B (zh) 2022-01-07
TWI629278B (zh) 2018-07-11

Similar Documents

Publication Publication Date Title
JP6872550B2 (ja) 架橋されたピペリジン誘導体
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
EP3448838B1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
JP5753591B2 (ja) 架橋ピぺリジン誘導体
JP5934782B2 (ja) アミノ−ピリジン含有脾臓チロシンキナーゼ（Ｓｙｋ）阻害薬
US10703748B2 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
JP2018527329A (ja) Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体
WO2013052394A1 (en) 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
JP7111704B2 (ja) 二環式ヘテロアリール誘導体
TW202102495A (zh) Ｅｅｄ及ｐｒｃ２調節劑之巨環唑并吡啶衍生物
TW201815792A (zh) 橋聯哌啶衍生物
AU2017384481A1 (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors
WO2014153280A1 (en) 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
JP7012715B2 (ja) γ－セクレターゼモジュレーターとしてのトリアゾロピリジン
KR102611539B1 (ko) Gsk-3 억제제
HK1254787A1 (en) Bridged piperidine derivatives
HK1254787B (zh) 桥连哌啶衍生物
HK1190705A (en) Bridged piperidine derivatives
OA18588A (en) 1,1,1-Trifluoro-3-Hydroxypropan-2-yl Carbamate Derivatives and 1,1,1-Trifluoro-4Hydroxybutan-2-yl Carbamate Derivatives as Magl Inhibitors.
HK1190705B (en) Bridged piperidine derivatives
HK1262827A1 (en) Triazolopyridines as gamma-secretase modulators
HK1262827B (en) Triazolopyridines as gamma-secretase modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210419

R150 Certificate of patent or registration of utility model

Ref document number: 6872550

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250